Osteal Therapeutics, Inc. — Form D/A
Osteal Therapeutics, Inc. of DALLAS, TX, a company, filed a Form D amendment with the SEC on 2021-01-12. The offering totals $2.0M, of which $2.0M was reported sold. Industry: Pharmaceuticals.
Offering
- Filed: 2021-01-12
- Form: D/A
- Accession: 0001735936-21-000002
- Industry: Pharmaceuticals
- Exemptions: 06b
- Total offering: $2.0M
- Amount sold: $2.0M
- Investors: 25
- Date of first sale: 2020-11-06
- Security types: debt
- Revenue range: Decline to Disclose
- SEC file number: 021-381333
Issuer
- Name: Osteal Therapeutics, Inc.
- CIK: 0001735936
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Address: 4835 LYNDON B. JOHNSON FWY STE 635, DALLAS, TX, 75244
- Phone: (469) 809-2630
Officers, directors & promoters (16)
| Name | Role | Location |
|---|
| Jude Paganelli | Director | San Clemente, CA |
| Jude Paganelli | Executive Officer | San Clemente, CA |
| Erik Oros | Director | Sarasota, FL |
| David Thompson | Director | Los Angeles, CA |
| David Thompson | Executive Officer | Los Angeles, CA |
| Martin Sands | Director | New York, NY |
| Judson Cooper | Director | DALLAS, TX |
| Brian de Beaubien | Director | DALLAS, TX |
| Brian de Beaubien | Executive Officer | DALLAS, TX |
| Biren Mehta | Director | DALLAS, TX |
| Douglas Kohrs | Director | DALLAS, TX |
| David Cash | Director | DALLAS, TX |
| Rushu Luo | Director | DALLAS, TX |
| Sonal Patel | Director | DALLAS, TX |
| Renee Ryan | Director | Hayward, CA |
| Noam Krantz | Director | Dallas, TX |
Other filings by this issuer (6)
More